UChicago Medicine Primary Care e-Journal Club: Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

April 1, 2022 to April 30, 2022
This activity will use an asynchronous e-learning model to facilitate engagement of with high-impact updates in the primary care literature that will improve patient care.
This article describes a phase 3b open label randomized control trial that compared once weekly semaglutide with daily liraglutide for weight loss in overweight or obese adults over a 68 week follow-up period. This trial demonstrates dramatically improved efficacy for once weekly semaglutide without increasing adverse events.

Target Audience

This activity is designed for physicians and other healthcare professionals that provide primary care to patients at UChicago Medicine.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Compare the efficacy of newly approved once weekly semaglutide with daily liraglutide for use in chronic weight management;
  • Examine adverse event differences between once weekly semaglutide and daily liraglutide;
  • Discuss your experiences using GLP-1 agonists for weight management.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
For more information, please contact:
CME Coordinator Contact Name: 
Katherine Sullivan
CME Coordinator Contact Email: 
CME Coordinator Contact Phone: 
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Event starts: 
04/01/2022 - 12:00am
Event ends: 
04/30/2022 - 11:59pm
Activity opens: 
Activity expires: 
  George Weyer, MD
  Assistant Professor of Medicine



Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the conference end date. Requests to claim credit after three months will be subject to additional fees.
Registration: This course is only open to University of Chicago affiliates.
Click below for more information!

Please login or create an account to proceed.